FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2298069204> ?p ?o ?g. }

• W2298069204 endingPage "64" @default.
• W2298069204 startingPage "57" @default.
• W2298069204 abstract "2-chlorodeoxyadenosine (2-CDA) is a new purine analogue which has been shown to be highly active in lymphoproliferative disorders. In this clinical trial we assessed 2-CDA toxicity and response rate in patients with various haematological malignancies who were heavily pre-treated and mostly refractory to standard treatment regimens.Twenty-two refractory patients, 51 relapsing after standard chemotherapy and seven non-pre-treated patients were treated in a non-randomized prospective phase II multicentric study. Their median age was 54 years (range 18-84) and 56 of them were male. Thirty-one had non-Hodgkin's lymphoma (NHL), 11 chronic lymphocytic leukaemia (CLL), 1 prolymphocytic leukaemia (PLL), 13 hairy-cell leukaemia (HCL), 2 mycosis fungoides (MF), 3 multiple myeloma, 7 acute myeloblastic leukaemia (AML), 2 acute lymphoblastic leukaemia (ALL), 6 chronic myeloid leukaemia (CML) in blast crisis, 2 Hodgkin's disease, 1 Waldenström's macroglobulinemia and 1 Langerhans histiocytosis. 2-CDA 0.1 mg/kg/day was given as a continuous intravenous infusion for 7 days and recycled every 4 weeks.One hundred thirty-two courses of 2-CDA were administered to 80 patients, 76 of whom were evaluable for response. A) Toxicity: Myelosuppression: Neutropenia to over 50% of initial value occurred in 46% of patients, thrombocytopenia in 8%, and lymphopenia < 0.5 x 10(9)/l was seen in 41%. Infections occurred in 34/80 patients (43%). The risk of severe infections (WHO grades 3-4) correlated with increasing number of years after first diagnosis (p = 0.01) and low lymphocyte counts on days 1 and/or 14 (p = 0.04); 21 infections were opportunistic. B) Response: 70% patients with lymphoproliferative disorders of low malignancy attained complete or partial response (low-grade NHL 12/16, CLL + PLL 9/12, HCL 13/13, MF 2/2, myeloma 0/3); in patients with AML, ALL, CML in myeloid (n = 4) or lymphoid (n = 2) blast crisis and high-grade lymphoma responses were seen in only 11%. Response was inversely related to the number of pretreatments (p = 0.045). In responding NHL patients the mean lymphocyte count on day 14 of cycle 1 was significantly lower (median 0.6 x 10(9)/l) than that of non-responders (1.2 x 10(9)/l, p = 0.04).2-CDA had a high activity even in heavily pretreated and refractory patients with low-grade lymphoproliferative disorders. In contrast to previously published studies, infections, mainly opportunistic, were a serious side effect in our study. In patients with severe lymphopenia at therapy initiation, the value of prophylactic anti-infective treatment should be studied." @default.
• W2298069204 created "2016-06-24" @default.
• W2298069204 creator A5000513493 @default.
• W2298069204 creator A5000852530 @default.
• W2298069204 creator A5001536238 @default.
• W2298069204 creator A5009257532 @default.
• W2298069204 creator A5021127401 @default.
• W2298069204 creator A5037216755 @default.
• W2298069204 creator A5043629300 @default.
• W2298069204 creator A5046320580 @default.
• W2298069204 creator A5049605313 @default.
• W2298069204 creator A5070351685 @default.
• W2298069204 creator A5081971224 @default.
• W2298069204 creator A5082943014 @default.
• W2298069204 date "1994-01-01" @default.
• W2298069204 modified "2023-09-25" @default.
• W2298069204 title "High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias" @default.
• W2298069204 cites W149140897 @default.
• W2298069204 cites W1792577025 @default.
• W2298069204 cites W1840080876 @default.
• W2298069204 cites W1896652710 @default.
• W2298069204 cites W1926511128 @default.
• W2298069204 cites W1968102342 @default.
• W2298069204 cites W1971022670 @default.
• W2298069204 cites W1983066514 @default.
• W2298069204 cites W1995570857 @default.
• W2298069204 cites W1999516176 @default.
• W2298069204 cites W2000812551 @default.
• W2298069204 cites W2005416337 @default.
• W2298069204 cites W2015931113 @default.
• W2298069204 cites W2025697028 @default.
• W2298069204 cites W2048415378 @default.
• W2298069204 cites W2074880157 @default.
• W2298069204 cites W2076668534 @default.
• W2298069204 cites W2077561098 @default.
• W2298069204 cites W2079317120 @default.
• W2298069204 cites W2081409366 @default.
• W2298069204 cites W2084217994 @default.
• W2298069204 cites W2086984633 @default.
• W2298069204 cites W2096748176 @default.
• W2298069204 cites W2166014786 @default.
• W2298069204 cites W2167805334 @default.
• W2298069204 cites W2218543073 @default.
• W2298069204 cites W2314659489 @default.
• W2298069204 cites W2317201497 @default.
• W2298069204 cites W2334996101 @default.
• W2298069204 cites W2398183686 @default.
• W2298069204 cites W2409596971 @default.
• W2298069204 cites W2551191294 @default.
• W2298069204 cites W4232231972 @default.
• W2298069204 cites W4233161682 @default.
• W2298069204 cites W4239548556 @default.
• W2298069204 cites W4240037281 @default.
• W2298069204 cites W4252269941 @default.
• W2298069204 cites W4252803386 @default.
• W2298069204 cites W4256601499 @default.
• W2298069204 cites W2001918786 @default.
• W2298069204 doi "https://doi.org/10.1093/oxfordjournals.annonc.a058693" @default.
• W2298069204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7909685" @default.
• W2298069204 hasPublicationYear "1994" @default.
• W2298069204 type Work @default.
• W2298069204 sameAs 2298069204 @default.
• W2298069204 citedByCount "64" @default.
• W2298069204 countsByYear W22980692042013 @default.
• W2298069204 countsByYear W22980692042014 @default.
• W2298069204 countsByYear W22980692042015 @default.
• W2298069204 countsByYear W22980692042016 @default.
• W2298069204 countsByYear W22980692042018 @default.
• W2298069204 countsByYear W22980692042019 @default.
• W2298069204 countsByYear W22980692042020 @default.
• W2298069204 countsByYear W22980692042023 @default.
• W2298069204 crossrefType "journal-article" @default.
• W2298069204 hasAuthorship W2298069204A5000513493 @default.
• W2298069204 hasAuthorship W2298069204A5000852530 @default.
• W2298069204 hasAuthorship W2298069204A5001536238 @default.
• W2298069204 hasAuthorship W2298069204A5009257532 @default.
• W2298069204 hasAuthorship W2298069204A5021127401 @default.
• W2298069204 hasAuthorship W2298069204A5037216755 @default.
• W2298069204 hasAuthorship W2298069204A5043629300 @default.
• W2298069204 hasAuthorship W2298069204A5046320580 @default.
• W2298069204 hasAuthorship W2298069204A5049605313 @default.
• W2298069204 hasAuthorship W2298069204A5070351685 @default.
• W2298069204 hasAuthorship W2298069204A5081971224 @default.
• W2298069204 hasAuthorship W2298069204A5082943014 @default.
• W2298069204 hasBestOaLocation W22980692041 @default.
• W2298069204 hasConcept C126322002 @default.
• W2298069204 hasConcept C2776694085 @default.
• W2298069204 hasConcept C2776755627 @default.
• W2298069204 hasConcept C2777063308 @default.
• W2298069204 hasConcept C2777866208 @default.
• W2298069204 hasConcept C71924100 @default.
• W2298069204 hasConcept C90924648 @default.
• W2298069204 hasConceptScore W2298069204C126322002 @default.
• W2298069204 hasConceptScore W2298069204C2776694085 @default.
• W2298069204 hasConceptScore W2298069204C2776755627 @default.
• W2298069204 hasConceptScore W2298069204C2777063308 @default.
• W2298069204 hasConceptScore W2298069204C2777866208 @default.
• W2298069204 hasConceptScore W2298069204C71924100 @default.

• next